https://www.nextcellpharma.com https://www.nextcellpharma.com/en/about-nextcell https://www.nextcellpharma.com/en/contact https://www.nextcellpharma.com/en/cookie-policy https://www.nextcellpharma.com/cookiepolicy https://www.nextcellpharma.com/en/home https://www.nextcellpharma.com/integritetsskyddspolicy https://www.nextcellpharma.com/investerare https://www.nextcellpharma.com/en/investors https://www.nextcellpharma.com/kontakt https://www.nextcellpharma.com/en/news https://www.nextcellpharma.com/en/no-access https://www.nextcellpharma.com/nyheter https://www.nextcellpharma.com/om-nextcell https://www.nextcellpharma.com/pressmeddelanden-arkiv https://www.nextcellpharma.com/studie https://www.nextcellpharma.com/en/our-product-portfolio https://www.nextcellpharma.com/tilltrade-nekat https://www.nextcellpharma.com/var-produktportfolj https://www.nextcellpharma.com/nav/success-sv https://www.nextcellpharma.com/nav/failed-sv https://www.nextcellpharma.com/nav/success-en https://www.nextcellpharma.com/nav/failed-en https://www.nextcellpharma.com/en/press-releases-archive https://www.nextcellpharma.com/en/study https://www.nextcellpharma.com/en/data-integrity-and-privacy-policy https://www.nextcellpharma.com/en/extraordinary-general-meeting-2026 https://www.nextcellpharma.com/sv-press-releases/alla-patienter-har-behandlats-i-protrans-young-studien https://www.nextcellpharma.com/sv-press-releases/analyst-group-aktieanalys-pa-nextcell-pharma-kapitalinjektion-mojliggor-fardigstallande-av-fas-i-ii https://www.nextcellpharma.com/sv-press-releases/analyst-group-aktieanalys-pa-nextcell-pharma-kliniska-framgangar-motiverar-en-hogre-vardering https://www.nextcellpharma.com/sv-press-releases/analyst-group-aktieanalys-pa-nextcell-pharma-unikt-stamcellsbolag-med-potential-inom-flera-sjukdomsomraden https://www.nextcellpharma.com/sv-press-releases/anders-essen-moller-avgar-som-ordforande-i-nextcells-styrelse-med-anledning-av-halsoskal https://www.nextcellpharma.com/sv-press-releases/anders-essen-moller-tecknar-hela-sin-andel-i-nextcell-pharmas-foretradesemission https://www.nextcellpharma.com/sv-press-releases/angela-vollstedt-ansluter-till-nextcells-board-of-advisors---starker-strategi-for-tillverkning-och-licensiering https://www.nextcellpharma.com/sv-press-releases/ansokan-om-klinisk-lakemedelsprovning-inlamnad-till-lakemedelsverket-protrans-2 https://www.nextcellpharma.com/sv-press-releases/arsredovisning-2018-2019 https://www.nextcellpharma.com/sv-press-releases/arsredovisning-2019-2020 https://www.nextcellpharma.com/sv-press-releases/arsredovisning-2020-2021 https://www.nextcellpharma.com/sv-press-releases/arsredovisning-2021-2022 https://www.nextcellpharma.com/sv-press-releases/arsredovisning-2022-2023 https://www.nextcellpharma.com/sv-press-releases/arsredovisning-2023-2024 https://www.nextcellpharma.com/sv-press-releases/artikel-i-lakartidningen-om-gen-och-cellterapi https://www.nextcellpharma.com/sv-press-releases/aterpublicering-av-nextcell-tillkannager-strategiskt-samarbete-med-fujifilm-biosciences https://www.nextcellpharma.com/sv-press-releases/attaarige-hugo---en-vardag-med-typ-1-diabetes-och-deltagande-i-protrans-studien https://www.nextcellpharma.com/sv-press-releases/banbrytande-multiplicering-av-blodstamceller https://www.nextcellpharma.com/sv-press-releases/barndiabetesstudie-med-stamceller-godkand https://www.nextcellpharma.com/sv-press-releases/barndiabetesstudien-far-gront-ljus-att-behandla-aldersgruppen-7---11-ar https://www.nextcellpharma.com/sv-press-releases/behandlingsstart-med-medeldos-i-covid-19 https://www.nextcellpharma.com/sv-press-releases/behandlingstart-med-hogdos-av-protrans-for-svar-lunginflammation https://www.nextcellpharma.com/sv-press-releases/biostock-nextcell-pharma-ska-passera-flera-milstolpar-via-emission https://www.nextcellpharma.com/sv-press-releases/biostock-nextcell-pharma-vill-stopa-om-behandlingsparadigmet-for-diabetes https://www.nextcellpharma.com/sv-press-releases/biostock-nextcell-pharmas-vd-har-en-klar-vision https://www.nextcellpharma.com/sv-press-releases/biostock-nyemission-ska-mojliggora-fas-iii-studie-for-nextcell-pharmas-stamcellslakemedel https://www.nextcellpharma.com/sv-press-releases/bokslutskommunike-2018-09-01-2019-08-31 https://www.nextcellpharma.com/sv-press-releases/bredare-halsofordelar-med-protrans-for-behandling-av-typ-1-diabetes https://www.nextcellpharma.com/sv-press-releases/cellaviva-leverar-stamceller-for-behandling-av-allvarlig-blodsjukdom https://www.nextcellpharma.com/sv-press-releases/covid-19-patient-behandlad-med-protrans https://www.nextcellpharma.com/sv-press-releases/cso-lindsay-davies-ar-motesordforande-for-isct-europe-2024 https://www.nextcellpharma.com/sv-press-releases/de-forsta-barnen-har-behandlats-i-den-yngre-aldersgruppen-i-protrans-young-studien https://www.nextcellpharma.com/sv-press-releases/delarsrapport-1-2019-2020 https://www.nextcellpharma.com/sv-press-releases/delarsrapport-1-kvartalet https://www.nextcellpharma.com/sv-press-releases/delarsrapport-1-kvartalet-uppdaterar-sin-situation https://www.nextcellpharma.com/sv-press-releases/delarsrapport-2016-09-01-2017-05-31 https://www.nextcellpharma.com/sv-press-releases/delarsrapport-2018-09-01-2019-05-31 https://www.nextcellpharma.com/sv-press-releases/delgruppsanalys-nextcell-presenterar-preliminara-1-arsresultat-fran-den-aldre-aldersgruppen-i-protrans-young https://www.nextcellpharma.com/sv-press-releases/den-kanadensiska-provningen-for-protrans-i-covid-19-utokas-till-en-multicenterstudie https://www.nextcellpharma.com/sv-press-releases/diabetespatienter-behandlade-med-protrans-stamceller-i-fas-ii-studie https://www.nextcellpharma.com/sv-press-releases/diamyd-medical-ab-tecknar-ytterligare-post-i-nextcells-pagaende-emission-av-units https://www.nextcellpharma.com/sv-press-releases/diskussioner-om-samgaende-mellan-nextcell-pharma-ab-och-idogen-ab-avbryts https://www.nextcellpharma.com/sv-press-releases/en-del-av-projektet-visionsdriven-halsa https://www.nextcellpharma.com/sv-press-releases/en-enda-behandling-med-protrans-visar-effekt-pa-typ-1-diabetes-i-over-5-ar https://www.nextcellpharma.com/sv-press-releases/en-uppdatering-om-nextcell-pharma-och-nordic-tech-house https://www.nextcellpharma.com/sv-press-releases/entreprenoren-pingis-hadenius-foreslas-till-nextcells-styrelse https://www.nextcellpharma.com/sv-press-releases/eric-strati-ansluter-till-nextcells-board-of-advisors-for-att-stodja-den-kommersiella-strategin-for-protrans https://www.nextcellpharma.com/sv-press-releases/europeiska-patentverket-amnar-bevilja-patent-for-selektionsalgoritmen https://www.nextcellpharma.com/sv-press-releases/familjesparande-av-stamceller-marknadsfors-pa-underbara-barn-pa-stockholmsmassan-13-15-oktober-2017 https://www.nextcellpharma.com/sv-press-releases/first-trading-day-on-nasdaq-first-north-for-nextcell https://www.nextcellpharma.com/sv-press-releases/flaggningsmeddelande-styrelseordforande-i-nextcell-pharma-abokar-sitt-innehav https://www.nextcellpharma.com/sv-press-releases/forlangt-tillstand-att-bedriva-vavnadsinrattning-fran-ivo https://www.nextcellpharma.com/sv-press-releases/forskare-positiva-till-behandling-med-stamceller-fran-navelstrang-for-barn-med-cp-skada https://www.nextcellpharma.com/sv-press-releases/forsta-aldersgruppen-behandlad-i-pediatrisk-diabetesstudie-med-protrans https://www.nextcellpharma.com/sv-press-releases/forsta-dag-for-handel-i-stamcellsbolaget-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/forsta-dag-for-handel-med-bta-2-i-nextcell-pharma https://www.nextcellpharma.com/sv-press-releases/forsta-delen-av-barndiabetesstudien-med-nextcells-protrans-ar-fardigbehandlad https://www.nextcellpharma.com/sv-press-releases/forsta-diabetespatienten-behandlad-med-protrans-stamceller https://www.nextcellpharma.com/sv-press-releases/forsta-diabetespatienten-har-fatt-upprepad-behandling-med-protrans https://www.nextcellpharma.com/sv-press-releases/forsta-handelsdag-pa-nasdaq-first-north-for-nextcell https://www.nextcellpharma.com/sv-press-releases/forsta-ungdomarna-med-typ-1-diabetes-behandlade-med-protrans-i-fas-ii-delen https://www.nextcellpharma.com/sv-press-releases/fortsatt-tillstand-fran-lakemedelsverket https://www.nextcellpharma.com/sv-press-releases/fortydligande-om-utfall-i-foretradesemissionen https://www.nextcellpharma.com/sv-press-releases/halvarsrapport https://www.nextcellpharma.com/sv-press-releases/inbjudna-till-paneldiskussion-varlden-efter-covid-19 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ-2 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ-264c9 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ-6 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ-7 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ-79852 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-arsstamma-i-nextcell-pharma-ab-publ-c8300 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-extra-bolagsstamma-i-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/kallelse-till-extra-bolagsstamma-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kallelse-till-extra-bolagsstamma-i-nextcell-pharma-ab-publ-0d934 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-extra-bolagsstamma-i-nextcell-pharma-ab-publ-772c9 https://www.nextcellpharma.com/sv-press-releases/kallelse-till-extra-bolagstamma-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kanadensisk-studie-for-protrans-i-covid-19 https://www.nextcellpharma.com/sv-press-releases/kommande-evenemang-och-konferenser-for-nxtcl https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-2021-i-cellterapibolaget-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-2022 https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-2023-i-cellterapibolaget-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-2024-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-i-nextcell-pharma-ab-publ-2 https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamma-i-nextcell-pharma-ab-publ-3 https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-arsstamman-2020-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-extra-bolagsstamma-i-nextcell-pharma-ab-publ https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-extra-bolagsstamma-i-nextcell-pharma-ab-publ-2024-05-27 https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-extra-bolagsstamma-i-nextcell-pharma-ab-publ-99935 https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-extra-bolagsstamma-i-nextcell-pharma-ab-publ-ea5ac https://www.nextcellpharma.com/sv-press-releases/kommunike-fran-extra-bolagsstamma-i-nextcell-pharma-ab-publ-f https://www.nextcellpharma.com/sv-press-releases/korrigering-nextcell-kallar-till-arsstamma https://www.nextcellpharma.com/sv-press-releases/lakemedelsverket-godkanner-delgruppsanalys-i-nextcells-protrans-young-studie https://www.nextcellpharma.com/sv-press-releases/langtidseffekt-av-upprepad-protrans-behandling-efter-6-ar https://www.nextcellpharma.com/sv-press-releases/ledande-europeisk-stamcellsaktor-investerar-i-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/lovande-resultat-fran-stamcellsstudie-med-protrans https://www.nextcellpharma.com/sv-press-releases/market-notice-135-19-information-regarding-the-rights-issue-from-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/market-notice-191-19-last-day-of-trading-in-nextcell-pharma-abs-bta https://www.nextcellpharma.com/sv-press-releases/market-notice-192-19-information-regarding-nextcell-pharma-abs-bta-2 https://www.nextcellpharma.com/sv-press-releases/market-notice-96-19-trading-halt-in-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/marknadsmeddelande-196-17-nextcell-pharma-ab-noteras-pa-aktietorget-den-13-juli-2017 https://www.nextcellpharma.com/sv-press-releases/marknadsmeddelande-207-18-sista-dag-for-handel-med-teckningsoption-serie-to-1-i-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/marknadsmeddelande-37-18-andring-av-kortnamn-i-nextcell-pharma-ab-s-aktie-och-teckningsoption https://www.nextcellpharma.com/sv-press-releases/med-protrans-young-fordubblas-var-marknadspotential https://www.nextcellpharma.com/sv-press-releases/nextcell-ansoker-om-metodpatent-for-prediktion https://www.nextcellpharma.com/sv-press-releases/nextcell-ar-inbjuden-talare-vid-advanced-therapy-congress-i-london https://www.nextcellpharma.com/sv-press-releases/nextcell-beslutar-att-foresla-riktad-nyemission-om-15-msek https://www.nextcellpharma.com/sv-press-releases/nextcell-beviljas-amerikanskt-patent-for-msc-prediktionsalgoritm https://www.nextcellpharma.com/sv-press-releases/nextcell-cellterapi-visar-pa-langtidseffekt-i-tva-oberoende-diabetesstudier-protrans-repeat-och-protrans-obs-direktsand-presentation https://www.nextcellpharma.com/sv-press-releases/nextcell-delagare-i-samarbetsbolag-for-car-t https://www.nextcellpharma.com/sv-press-releases/nextcell-deltar-pa-konferens-for-varldsledande-cellterapier https://www.nextcellpharma.com/sv-press-releases/nextcell-etablerar-dotterbolaget-qvance-for-att-mota-nordisk-efterfragan-av-kvalitetsanalyser https://www.nextcellpharma.com/sv-press-releases/nextcell-far-godkant-att-ge-upprepad-dos-av-protrans-i-ny-klinisk-provning-protrans-repeat https://www.nextcellpharma.com/sv-press-releases/nextcell-firar-ett-ar-som-noterat-bolag https://www.nextcellpharma.com/sv-press-releases/nextcell-fortsatter-sin-verksamhetsutveckling https://www.nextcellpharma.com/sv-press-releases/nextcell-genomfor-riktad-emission-av-units-till-garanter-i-samband-med-den-genomforda-foretradesemissionen https://www.nextcellpharma.com/sv-press-releases/nextcell-godkanns-for-handel-pa-nasdaq-first-north https://www.nextcellpharma.com/sv-press-releases/nextcell-har-formellt-startat-sitt-eurostars-finansierade-projekt-bioscale https://www.nextcellpharma.com/sv-press-releases/nextcell-har-nu-tva-parallella-kliniska-studier-igang-protrans-1-och-protrans-repeat-som-startar-idag https://www.nextcellpharma.com/sv-press-releases/nextcell-i-diskussioner-om-patienter-med-covid-19 https://www.nextcellpharma.com/sv-press-releases/nextcell-i-svensk-life-science-delegation-till-hongkong https://www.nextcellpharma.com/sv-press-releases/nextcell-inbjuden-att-presentera-i-tokyo https://www.nextcellpharma.com/sv-press-releases/nextcell-inbjuden-presentator-pa-international-society-for-cell-and-gene-therapy-mote-i-paris https://www.nextcellpharma.com/sv-press-releases/nextcell-inbjuden-talare-vid-european-wound-management-association-i-milano https://www.nextcellpharma.com/sv-press-releases/nextcell-inbjudna-att-tala-pa-advance-therapies-congress-i-london https://www.nextcellpharma.com/sv-press-releases/nextcell-inbjudna-att-tala-pa-prestigefyllda-advanced-therapy-week-i-usa https://www.nextcellpharma.com/sv-press-releases/nextcell-ingar-memorandum-of-agreement-med-china-general-consulting-investment-co-ltd https://www.nextcellpharma.com/sv-press-releases/nextcell-inleder-samarbete-med-opticell---starker-sin-verksamhet-inom-cellhantering https://www.nextcellpharma.com/sv-press-releases/nextcell-investerar-i-car-t-behandling https://www.nextcellpharma.com/sv-press-releases/nextcell-investerar-i-cellavivas-danska-verksamhet-med-nytt-kopenhamns-kontor https://www.nextcellpharma.com/sv-press-releases/nextcell-kallar-till-arsstamma https://www.nextcellpharma.com/sv-press-releases/nextcell-kallar-till-arsstamma-3 https://www.nextcellpharma.com/sv-press-releases/nextcell-lyfts-fram-i-fujifilms-strategiska-vision-enligt-gen https://www.nextcellpharma.com/sv-press-releases/nextcell-meddelar-strategiskt-samarbete-med-fujifilm-irvine-scientific https://www.nextcellpharma.com/sv-press-releases/nextcell-medverkar-i-jetros-japan-entry-acceleration-program https://www.nextcellpharma.com/sv-press-releases/nextcell-noterat-pa-life-science-hotlist https://www.nextcellpharma.com/sv-press-releases/nextcell-och-cellaviva-lyfts-fram-av-ki-innovations https://www.nextcellpharma.com/sv-press-releases/nextcell-offentliggor-prospekt-med-anledning-av-foretradesemission-av-units-om-cirka-40-1-msek https://www.nextcellpharma.com/sv-press-releases/nextcell-offentliggor-tillaggsprospekt-avseende-foretradesemissionen https://www.nextcellpharma.com/sv-press-releases/nextcell-okar-marknadspotentialen-och-minskar-risken-for-protrans-kliniska-provingsprogram-i-typ-1-diabetes https://www.nextcellpharma.com/sv-press-releases/nextcell-pa-investerarjakten https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-ansoker-om-klinisk-provning-med-protrans-tm https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-anstaller-cfo https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-deltar-i-bio-europe-2024-och-valkomnar-besok-av-energi--och-naringslivsminister-ebba-busch https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-godkanda-for-notering-pa-aktietorget-och-uppdatering-om-bolagets-emission-av-units https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-idag-inleds-teckningstiden-i-emissionen-av-units https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-kommenterar-handelsstoppet-den-25-april-2019 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-kommer-att-delta-i-flera-evenemang-under-september https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-meddelar-cfo-forandring https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-offentliggor-informationsmemorandum-avseende-foretradesemission-vars-teckningsperiod-startar-idag https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-offentliggor-prospekt-avseende-foretradesemissionen-och-meddelar-avsikt-om-listbyte-till-nasdaq-first-north-i-juli https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-offentliggor-tillaggsprospekt https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-offentliggor-tillaggsprospekt-2 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-offentliggor-utfallet-i-emissionen-av-units https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-offentliggorande-av-prospekt-infor-emission-av-units https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-s-foretradesemission-kraftigt-overtecknad https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ab-s-storsta-aktieagare-diamyd-medical-ab-nyttjar-samtliga-innehavda-teckningsoptioner-av-serie-to1 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-andrar-ticker-till-nxtcl https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-ansoker-om-patent https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-bestaller-protrans-tm-stamceller-for-klinisk-studie https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-byter-certified-adviser-till-redeye-ab https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-completes-a-directed-share-issue-to-a-strategic-partner https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-erhaller-avsiktsforklaringar-teckningsforbindelser-och-toppgarantier-avseende-nyttjande-av-to2 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-erhaller-tillstand-for-partihandel https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-erhaller-ytterligare-avsiktsforklaringar-avseende-nyttjande-av-to2 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-foretagspresentationer https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-genomfor-riktad-nyemission-till-en-strategisk-partner https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-har-beslutat-om-uppdaterad-tillvaxtstrategi https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-har-sammanstallt-en-q-a https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-inbjuden-talare-vid-world-advanced-therapies-regenerative-medicine-congress https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-initierar-stamcellsstudie-for-typ-1-diabetes-med-protrans https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-introducerar-sparande-av-stamceller-fran-vuxna https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-lamnar-in-ytterligare-en-patentansokan https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-bokslutskommunike-2021-2022 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-bokslutskommunike-2022-2023 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-bokslutskommunike-2023-2024 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-bokslutskommunike-2024-2025 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-bokslutskommunike-for-2019-2020 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-bokslutskommunike-for-2020-2021 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-1-for-2020-2021 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-1-for-2021-2022 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-1-for-2022-2023 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-1-for-2023-2024 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-1-for-2024-2025 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-1-for-2024-2025-a4c74 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-2-for-2020-2021 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-2-for-2021-2022 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-2-for-2022-2023 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-2-for-2023-2024 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-2-for-2024-2025 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-3-for-2020-2021 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-3-for-2021-2022 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-3-for-2022-2023 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-3-for-2023-2024 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-3-for-2024-2025 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-4-for-2024-2025 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-for-september-2019-februari-2020 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-delarsrapport-for-september-2019-maj-2020 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-tillaggsprospekt https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentliggor-utfall-av-nyttjande-av-to2-och-beslutar-om-riktade-nyemissioner-till-garanter https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-offentligor-propsekt-med-anledning-av-foretradesemissionen https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-presenterar-pa-konferensen-advanced-therapies-europe https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-presenterar-pa-redeyetheme-regenerative-medicine-cell-therapy https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-presenterar-pa-redeyetheme-regenerative-medicine-cell-therapy-aeeab https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-publicerar-arsredovisning-2024-2025 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-publicerar-historiska-jamforelsekvartal https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-publicerar-idag-sin-arsredovisning-2016-2017 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-publicerar-kvartalsrapport-tre-2017-2018 https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-rekryterar-eric-gustafsson-som-ny-cfo https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-sammanfattar-laget-i-sin-forsta-kvartalsrapport https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-uppdaterar-sin-situation-i-en-fjarde-kvartalsrapport https://www.nextcellpharma.com/sv-press-releases/nextcell-pharma-valkomnar-consensus-sverige-select-som-ny-aktieagare https://www.nextcellpharma.com/sv-press-releases/nextcell-pharmas-foretradesemission-overtecknad https://www.nextcellpharma.com/sv-press-releases/nextcell-pharmas-forsta-leverans-av-protrans https://www.nextcellpharma.com/sv-press-releases/nextcell-pharmas-kliniska-provning-uppmarksammas-pa-tv3-sanda-diabetesgalan https://www.nextcellpharma.com/sv-press-releases/nextcell-pharmas-stamcellsstudie-i-typ-1-diabetes-far-gront-ljus-fran-lakemedelsverket https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-detaljer-fran-den-administrativa-delgruppsanalysen-av-protrans-young https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-framsteg-pa-swiss-nordic-bio-2020 https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-kliniska-fas-ii-data-vid-isct-2021 https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-kvartalsrapport https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-resultat-fran-interimsanalys-idag-kl-15-00 https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-status-i-pagaende-studie-vid-nordic-life-science-days https://www.nextcellpharma.com/sv-press-releases/nextcell-presenterar-strategisk-uppdatering-om-fokuserad-marknadsutveckling-med-hongkong-som-port-till-den-kinesiska-marknaden https://www.nextcellpharma.com/sv-press-releases/nextcell-publicerar-debattartikel-med-isct https://www.nextcellpharma.com/sv-press-releases/nextcell-publicerar-idag-sin-halvarsrapport https://www.nextcellpharma.com/sv-press-releases/nextcell-publicerar-investerarbrev https://www.nextcellpharma.com/sv-press-releases/nextcell-samarbetar-med-t-a-d-1-och-t1dappen https://www.nextcellpharma.com/sv-press-releases/nextcell-soker-patent-for-behandling-av-covid-19-med-protrans https://www.nextcellpharma.com/sv-press-releases/nextcell-starker-organisationen-for-fortsatt-tillvaxt https://www.nextcellpharma.com/sv-press-releases/nextcell-stottar-protrans-studie-for-barn-och-ungdomar https://www.nextcellpharma.com/sv-press-releases/nextcell-tecknar-avtal-om-ny-vavnadsprodukt https://www.nextcellpharma.com/sv-press-releases/nextcell-tilldelas-eurostar-finansiering-for-utveckling-av-inovativ-produktionsplattform-for-cellterapier https://www.nextcellpharma.com/sv-press-releases/nextcell-tillsatter-en-interim-chief-financial-officer https://www.nextcellpharma.com/sv-press-releases/nextcell-uppdaterar-infor-nls-days https://www.nextcellpharma.com/sv-press-releases/nextcell-upphandlar-toppgaranti-i-pagaende-foretradesemission https://www.nextcellpharma.com/sv-press-releases/nextcell-utvalda-att-delta-i-eit-health-start-smart-global https://www.nextcellpharma.com/sv-press-releases/nextcell-utveckling-och-natverkande https://www.nextcellpharma.com/sv-press-releases/nextcells-biobank-cellaviva-beviljas-tillstand-fran-ivo-for-att-hantera-stamceller-fran-fettvavnad https://www.nextcellpharma.com/sv-press-releases/nextcells-cso-far-fortroendeuppdrag-inom-global-branschorganisation https://www.nextcellpharma.com/sv-press-releases/nextcells-cso-invald-i-styrelsen-for-atmp-sweden https://www.nextcellpharma.com/sv-press-releases/nextcells-cso-nominerad-till-isct-european-regional-secretary- https://www.nextcellpharma.com/sv-press-releases/nextcells-cso-nominerad-till-vice-president-for-international-society-of-cell-and-gene-therapy https://www.nextcellpharma.com/sv-press-releases/nextcells-dotterbolag-cellaviva-ges-tillstand-att-hantera-fosterhinnor https://www.nextcellpharma.com/sv-press-releases/nextcells-fas-ii-studie-ar-avslutad-fas-iii-forbereds https://www.nextcellpharma.com/sv-press-releases/nextcells-foretradesemission-overtecknad https://www.nextcellpharma.com/sv-press-releases/nextcells-foretradesemission-registrerad-omvandling-av-bta-2-till-aktier-faststalld https://www.nextcellpharma.com/sv-press-releases/nextcells-foretradesemission-tecknades-till-368-procent https://www.nextcellpharma.com/sv-press-releases/nextcells-foretradesemission-tecknades-till-368-procent-2 https://www.nextcellpharma.com/sv-press-releases/nextcells-forskningschef-vald-till-isct-s-europeiska-regionala-sekreterare https://www.nextcellpharma.com/sv-press-releases/nextcells-partner-pbkm-nyttjar-sina-teckningsoptioner-av-serie-to-1 https://www.nextcellpharma.com/sv-press-releases/nextcells-patentsokta-stamcellsalgoritm-genererar-intakter https://www.nextcellpharma.com/sv-press-releases/nextcells-seminarium-fas-i-ii-klinisk-studie-i-typ-i-diabetes-accepteras-for-publicering https://www.nextcellpharma.com/sv-press-releases/nextcells-styrelse-beslutar-om-en-foretradesemission-av-units-om-cirka-40-1-msek-villkorad-av-godkannande-fran-extra-bolagsstamma https://www.nextcellpharma.com/sv-press-releases/nextcells-vd-inbjuden-talare-pa-karolinska-institutet-konferens https://www.nextcellpharma.com/sv-press-releases/nextcells-vd-inbjuden-talare-pa-konferens-for-atmp https://www.nextcellpharma.com/sv-press-releases/nextcells-vd-inbjuden-talare-pa-nationell-konferens-om-kliniska-studier https://www.nextcellpharma.com/sv-press-releases/nextcells-vd-mathias-svahn-forklarar-de-senaste-resultaten-fran-protrans-young-studien-och-ger-sin-syn-pa-framtiden https://www.nextcellpharma.com/sv-press-releases/nordic-tech-house-investerar-i-stamcellsbolaget-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/nxtcl-s-bifirma-cellaviva-expanderar-till-danmark https://www.nextcellpharma.com/sv-press-releases/nxtcl-tillfors-cirka-12-9-msek-genom-optionsinlosen https://www.nextcellpharma.com/sv-press-releases/ny-vetenskaplig-artikel-publicerad-om-den-kliniska-studien-med-protrans https://www.nextcellpharma.com/sv-press-releases/nytt-samarbete-och-okad-digital-narvaro-cellaviva-rustar-for-tillvaxt https://www.nextcellpharma.com/sv-press-releases/nyttjande-av-teckningsoptioner-registrerat-hos-bolagsverket https://www.nextcellpharma.com/sv-press-releases/nyttjandeperioden-av-teckningsoptioner-av-serie-to-1-inleds-idag https://www.nextcellpharma.com/sv-press-releases/nyttjandeperioden-for-nextcell-pharmas-teckningsoptioner-av-serie-to2-inleds-idag https://www.nextcellpharma.com/sv-press-releases/offentliggorande-av-arsredovisning-2017-2018 https://www.nextcellpharma.com/sv-press-releases/offentliggorande-av-bokslutskommunike https://www.nextcellpharma.com/sv-press-releases/paminnelse-om-nyttjande-av-teckningsoptioner-av-serie-to-1 https://www.nextcellpharma.com/sv-press-releases/pediatrisk-diabetesstudie-med-protrans-pagar https://www.nextcellpharma.com/sv-press-releases/positiv-aterkoppling-gallande-den-pediatriska-planen-av-ema https://www.nextcellpharma.com/sv-press-releases/presentation-av-barndiabetesstudien-imorgon-onsdag https://www.nextcellpharma.com/sv-press-releases/presentation-av-de-positiva-resultaten-fran-protrans-2 https://www.nextcellpharma.com/sv-press-releases/protrans-cellterapi-ger-behandlingseffekt-3-5-ar-efter-behandling https://www.nextcellpharma.com/sv-press-releases/protrans-cellterapi-ger-langvarig-terapeutisk-effekt-pa-typ-1-diabetes-efter-endast-en-behandling https://www.nextcellpharma.com/sv-press-releases/protrans-cellterapi-kommer-beviljas-patentskydd-i-japan https://www.nextcellpharma.com/sv-press-releases/protrans-fas-ii-studie-vid-covid-19-accepterad-for-publicering-i-cytotherapy https://www.nextcellpharma.com/sv-press-releases/protrans-lyfts-fram-som-en-lovande-behandling-av-typ-1-diabetes-i-dagens-medicin https://www.nextcellpharma.com/sv-press-releases/protrans-observationsstudie-for-utvardering-av-langvarig-effekt https://www.nextcellpharma.com/sv-press-releases/protrans-och-nextcell-uppmarksammas-internationellt https://www.nextcellpharma.com/sv-press-releases/protrans-potential-diskuteras-med-professorer-inom-diabetes-och-stamceller https://www.nextcellpharma.com/sv-press-releases/protrans-potential-is-discussed-with-professors-in-diabetes-and-stem-cells https://www.nextcellpharma.com/sv-press-releases/protrans-presentation-at-advanced-therapies-congress-expo-2020 https://www.nextcellpharma.com/sv-press-releases/protrans-presentation-vid-advanced-therapies-congress-expo-2020 https://www.nextcellpharma.com/sv-press-releases/protrans-repeat-godkand-klinisk-provning-for-upprepad-behandling-av-patienter-med-diabetes https://www.nextcellpharma.com/sv-press-releases/protrans-stamceller-godkanns-for-klinsk-provning-pa-covid-19-patienter https://www.nextcellpharma.com/sv-press-releases/protrans-studie-i-covid-19-utokas-till-att-aven-omfatta-behandling-av-allvarlig-lunginflammation-orsakad-av-influensa-rs-och-hmp-virus https://www.nextcellpharma.com/sv-press-releases/protrans-studien-godkand-for-hogdosbehandling-med-i-fas-ii-delen https://www.nextcellpharma.com/sv-press-releases/protrans-visar-effekt-tva-ar-efter-upprepade-behandlingar https://www.nextcellpharma.com/sv-press-releases/protrans-visar-signifikant-effekt-vid-behandlig-av-diabetes https://www.nextcellpharma.com/sv-press-releases/qvance-ab-publicerar-artikel-om-partiklar-i-cell--och-genterapiprodukter-i-samarbete-med-isct https://www.nextcellpharma.com/sv-press-releases/qvance-tillkannager-partnerskap https://www.nextcellpharma.com/sv-press-releases/qvances-partnerskap-driver-innovation-inom-avancerade-terapier https://www.nextcellpharma.com/sv-press-releases/radgivande-mote-med-europeiska-lakemedelsmyndigheten-ema https://www.nextcellpharma.com/sv-press-releases/rattelse-av-kommunike-fran-arsstamma-i-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/rattelse-avseende-status-i-pagaende-studie https://www.nextcellpharma.com/sv-press-releases/rattelse-sex-av-nio-patienter-ar-fardigbehandlade-i-den-forsta-delen-av-fas-i-ii-studien-protrans-1 https://www.nextcellpharma.com/sv-press-releases/resultat-fran-aldersgruppen-i-barnstudien-protrans-young-vantas-i-april https://www.nextcellpharma.com/sv-press-releases/sakerhetskommitte-godkanner-studiebehandling-med-hogdos-av-protrans https://www.nextcellpharma.com/sv-press-releases/sakerhetskommitte-godkanner-studiebehandling-med-medelhogdos-av-protrans https://www.nextcellpharma.com/sv-press-releases/sakerhetskommitte-rekommenderar-start-av-del-2-av-stamcellsstudie-i-typ-1-diabetes https://www.nextcellpharma.com/sv-press-releases/samtliga-patienter-i-lagdosgruppen-behandlade-med-protrans https://www.nextcellpharma.com/sv-press-releases/samtliga-patienter-i-protrans-repeat-behandlade https://www.nextcellpharma.com/sv-press-releases/samtliga-patienter-med-allvarlig-lunginflammation-orsakad-av-virus-behandlade-i-protrans-v-studien https://www.nextcellpharma.com/sv-press-releases/sex-av-nio-patienter-i-protrans-1-studien-fas-ii-fardigbehandlade https://www.nextcellpharma.com/sv-press-releases/sex-patienter-nu-behandlade-med-nextcells-protrans-stamceller https://www.nextcellpharma.com/sv-press-releases/sexarsdata-visar-varaktig-sjukdomsmodifierande-effekt-av-protrans-vid-typ-1-diabetes https://www.nextcellpharma.com/sv-press-releases/sista-dag-for-handel-med-bta-1-i-nextcell-pharma https://www.nextcellpharma.com/sv-press-releases/sista-dag-for-handel-med-bta-i-nextcell-pharma-ab https://www.nextcellpharma.com/sv-press-releases/sista-dag-for-handel-med-teckningsoptioner-av-serie-to-1 https://www.nextcellpharma.com/sv-press-releases/sista-patientbesoket-i-doseskaleringsdelen-genomfort https://www.nextcellpharma.com/sv-press-releases/sista-patienten-i-protrans-1-fas-ii-delen-nu-behandlad https://www.nextcellpharma.com/sv-press-releases/sjuarsuppfoljning-fran-protrans-repeat-visar-varaktig-sjukdomsmodifierande-effekt-av-protrans-vid-typ-1-diabetes https://www.nextcellpharma.com/sv-press-releases/stamcellsbolaget-nextcell-investerar-i-egen-produktionsanlaggning https://www.nextcellpharma.com/sv-press-releases/stamcellsbolaget-nextcell-pharma-deltar-som-referenslaboratorium-i-nibsc-studie https://www.nextcellpharma.com/sv-press-releases/stamcellsbolaget-nextcell-pharma-erhaller-etikgodkannande https://www.nextcellpharma.com/sv-press-releases/stamcellsbolaget-nextcell-pharma-erhaller-etikgodkannande-for-klinisk-provning https://www.nextcellpharma.com/sv-press-releases/stamcellsbolaget-nextcell-pharma-forbereder-ansokan-om-pivotal-fas-iii-studie https://www.nextcellpharma.com/sv-press-releases/stamcellssparandet-fran-fodslar-okar-markant-for-nextcells-biobank-cellaviva https://www.nextcellpharma.com/sv-press-releases/stamscellsbanken-cellaviva-blir-sjalvstandigt-bolag-under-nextcell-pharma https://www.nextcellpharma.com/sv-press-releases/start-av-rekrytering-till-protrans-studie-for-behandling-av-covid-19 https://www.nextcellpharma.com/sv-press-releases/statusuppdatering-av-de-pagaende-kliniska-provningarna https://www.nextcellpharma.com/sv-press-releases/studie-publicerad-i-nature-medicine-visar-lovande-resultat-vid-alzheimers-sjukdom---starker-utvecklingen-av-protrans-hos-nextcell https://www.nextcellpharma.com/sv-press-releases/studiedesign-och-plan-for-nyligen-godkanda-covid-19-studien-med-protrans https://www.nextcellpharma.com/sv-press-releases/studiestart-for-protrans-i-covid-19 https://www.nextcellpharma.com/sv-press-releases/styrelse-och-ledning-tecknar-utover-teckningsataganden https://www.nextcellpharma.com/sv-press-releases/styrelsen-for-nextcell-pharma-beslutar-om-tidigare-meddelad-foretradesemission-om-150-msek https://www.nextcellpharma.com/sv-press-releases/styrelsen-i-nextcell-pharma-ab-beslutar-om-en-fullt-garanterad-foretradesemission-av-aktier-om-cirka-25-1-msek https://www.nextcellpharma.com/sv-press-releases/styrelsen-i-nextcell-pharma-ab-foreslar-foretradesemission-om-24-9-msek-och-kallar-till-extra-bolagstamma https://www.nextcellpharma.com/sv-press-releases/styrelsen-i-nextcell-pharma-avser-att-besluta-om-en-fullt-garanterad-foretrades-emission-om-upp-till-cirka-150-msek https://www.nextcellpharma.com/sv-press-releases/styrelsen-i-nextcell-pharma-meddelar-justerat-forslag-till-emissionsbemyndigande-infor-arsstamman-2020 https://www.nextcellpharma.com/sv-press-releases/summering-av-nyttjade-teckningsoptioner-av-styrelseledamoter-och-ledande-befattningshavare-i-nxtcl https://www.nextcellpharma.com/sv-press-releases/teckningsperioden-i-nextcells-foretradesemission-inleds-idag https://www.nextcellpharma.com/sv-press-releases/tidigare-meddelad-riktad-emission-till-nordic-tech-house-ab-registrerad-hos-bolagsverket https://www.nextcellpharma.com/sv-press-releases/tre-patienter-nu-behandlade-med-nextcells-protrans-stamceller https://www.nextcellpharma.com/sv-press-releases/uppdatering-angaende-nextcell-pharmas-ansokan-om-klinisk-provning https://www.nextcellpharma.com/sv-press-releases/uppdatering-av-nextcells-kliniska-provningar-med-protrans https://www.nextcellpharma.com/sv-press-releases/uppdatering-avseende-mojligt-samgaende-mellan-nextcell-pharma-ab-och-idogen-ab https://www.nextcellpharma.com/sv-press-releases/uppdatering-avseende-riktad-nyemission-till-nordic-tech-house https://www.nextcellpharma.com/sv-press-releases/upprepad-behandling-med-protrans-ar-immunologiskt-saker https://www.nextcellpharma.com/sv-press-releases/valberedningen-i-nextcell-pharma-ab-foreslar-eva-sjokvist-saers-som-ny-styrelseledamot https://www.nextcellpharma.com/sv-press-releases/vd-intervju-med-mathias-svahn https://www.nextcellpharma.com/sv-press-releases/vinnovaprojekt-for-cellbaserade-produkter https://www.nextcellpharma.com/sv-press-releases/ytterligare-en-batch-protrans-ar-frislappt-infor-nextcell-pharmas-pagaende-lakemedelsprovning https://www.nextcellpharma.com/press-releases/a-part-of-vision-driven-health https://www.nextcellpharma.com/press-releases/advisory-meeting-with-the-european-medicines-agency https://www.nextcellpharma.com/press-releases/all-patients-in-protrans-repeat-are-now-treated https://www.nextcellpharma.com/press-releases/all-patients-in-the-low-dose-group-treated-with-protrans https://www.nextcellpharma.com/press-releases/all-patients-successfully-treated-in-protrans-young-study https://www.nextcellpharma.com/press-releases/all-patients-with-severe-virus-induced-pneumonia-treated-in-the-protrans-v-study https://www.nextcellpharma.com/press-releases/an-additional-batch-of-protrans-is-released-prior-to-use-in-nextcell-pharmas-ongoing-clinical-trial https://www.nextcellpharma.com/press-releases/an-update-on-nextcell-pharma-and-nordic-tech-house https://www.nextcellpharma.com/press-releases/anders-essen-moller-resigns-as-chairman-of-the-board-of-directors-due-to-health-reasons https://www.nextcellpharma.com/press-releases/anders-essen-moller-subscribes-to-his-entire-stakes-in-nextcell-pharmas-right-issue https://www.nextcellpharma.com/press-releases/angela-vollstedt-joins-nextcell-pharma-s-board-of-advisors-to-strengthen-scientific-and-manufacturing-strategy-ahead-of-licensing-discussions https://www.nextcellpharma.com/press-releases/application-for-clinical-trial-submitted-to-the-medical-products-agency-protrans-2 https://www.nextcellpharma.com/press-releases/article-about-gene-and-cell-therapy https://www.nextcellpharma.com/press-releases/breakthrough-multiplication-of-blood-stem-cells https://www.nextcellpharma.com/press-releases/broader-health-benefits-of-protrans-in-treatment-of-type-1-diabetes https://www.nextcellpharma.com/press-releases/bulletin-from-the-extraordinary-general-meeting-of-nextcell-pharma-ab-publ https://www.nextcellpharma.com/press-releases/canadian-trial-for-protrans-in-covid-19 https://www.nextcellpharma.com/press-releases/cellaviva-becomes-an-independent-company-under-nextcell-pharma https://www.nextcellpharma.com/press-releases/cellaviva-delivers-stem-cells-to-treat-serious-blood-disease https://www.nextcellpharma.com/press-releases/correction-notice-to-attend-the-annual-general-meeting https://www.nextcellpharma.com/press-releases/covid-19-patient-treated-with-protrans https://www.nextcellpharma.com/press-releases/cso-lindsay-davies-co-chairs-isct-europe-2024-meeting https://www.nextcellpharma.com/press-releases/disclosure-notice-nextcell-pharma-abs-chairman-of-the-board-acquires-additional-shares https://www.nextcellpharma.com/press-releases/discussions-on-a-merger-between-nextcell-ab-and-idogen-ab-are-suspended https://www.nextcellpharma.com/press-releases/earlier-announced-directed-share-issue-to-nordic-tech-house-ab-registered-at-the-swedish-companies-registrations-office https://www.nextcellpharma.com/press-releases/eight-year-old-hugo---living-with-type-1-diabetes-and-participating-in-the-protrans-study https://www.nextcellpharma.com/press-releases/eric-strati-joins-nextcell-pharma-s-board-of-advisors-to-support-commercial-strategy-for-protrans https://www.nextcellpharma.com/press-releases/extended-permission-from-the-medical-products-agency https://www.nextcellpharma.com/press-releases/extended-tissue-establishment-authorization https://www.nextcellpharma.com/press-releases/family-saving-of-stem-cells-at-underbara-barn-held-atstockholm-international-fair-and-congresses-centre-13-15-october-2017 https://www.nextcellpharma.com/press-releases/final-patient-treated-in-the-phase-ii-part-of-the-protrans-1-trial https://www.nextcellpharma.com/press-releases/first-age-group-treated-in-paediatric-diabetes-study-with-protrans https://www.nextcellpharma.com/press-releases/first-day-of-trading-in-stem-cell-company-nextcell-pharma-ab https://www.nextcellpharma.com/press-releases/first-diabetes-patient-treated-with-protrans-stem-cells https://www.nextcellpharma.com/press-releases/first-pediatric-patients-treated-with-protrans-in-type-1-diabetes-phase-ii-study https://www.nextcellpharma.com/press-releases/half-year-report https://www.nextcellpharma.com/press-releases/interim-report-1-2019-2020 https://www.nextcellpharma.com/press-releases/interim-report-2018-09-01-2019-05-31 https://www.nextcellpharma.com/press-releases/invited-to-panel-discussion-post-covid-19-world https://www.nextcellpharma.com/press-releases/iterim-report-quarter-1 https://www.nextcellpharma.com/press-releases/last-day-of-trading-in-series-to-1-warrants https://www.nextcellpharma.com/press-releases/last-patient-last-visit-completed-in-the-dose-escalation-part https://www.nextcellpharma.com/press-releases/long-term-effects-with-repeated-protrans-treatment-after-6-years https://www.nextcellpharma.com/press-releases/new-collaboration-and-increased-digital-presence-cellaviva-is-gearing-for-growth https://www.nextcellpharma.com/press-releases/nextcell-and-cellaviva-are-highlighted-by-ki-innovations https://www.nextcellpharma.com/press-releases/nextcell-announces-eurostars-grant-for-developing-an-innovative-cell-therapy-production-platform https://www.nextcellpharma.com/press-releases/nextcell-announces-strategic-collaboration-with-fujifilm-irvine-scientific https://www.nextcellpharma.com/press-releases/nextcell-applies-for-prediction-methodology-patent https://www.nextcellpharma.com/press-releases/nextcell-approved-for-trading-on-nasdaq-first-north https://www.nextcellpharma.com/press-releases/nextcell-carries-out-a-directed-issue-of-units-to-guarantors-in-connection-with-the-completed-rights-issue https://www.nextcellpharma.com/press-releases/nextcell-celebrates-its-first-year-anniversary-as-a-listed-company https://www.nextcellpharma.com/press-releases/nextcell-cell-therapy-shows-long-term-effect-in-two-independent-diabetes-studies-protrans-repeat-and-protrans-obs-live-presentation https://www.nextcellpharma.com/press-releases/nextcell-ceo-invited-speaker-at-karolinska-institutet-conference https://www.nextcellpharma.com/press-releases/nextcell-ceo-invited-speaker-at-the-swedish-national-atmp-conference https://www.nextcellpharma.com/press-releases/nextcell-ceo-mathias-svahn-explains-the-latest-results-from-protrans-young-and-his-vision-for-the-way-forward https://www.nextcellpharma.com/press-releases/nextcell-collaborates-with-t-a-d-1-and-t1d-app https://www.nextcellpharma.com/press-releases/nextcell-continues-to-develop https://www.nextcellpharma.com/press-releases/nextcell-continuous-to-strengthen-development-and-collaborative-activities https://www.nextcellpharma.com/press-releases/nextcell-decides-to-propose-a-directed-share-issue-of-sek-15-million https://www.nextcellpharma.com/press-releases/nextcell-enters-car-t-joint-venture https://www.nextcellpharma.com/press-releases/nextcell-enters-into-memorandum-of-agreement-with-china-general-consulting-investment-co-ltd https://www.nextcellpharma.com/press-releases/nextcell-establishes-qvance-to-meet-the-nordic-s-need-for-quality-analytics https://www.nextcellpharma.com/press-releases/nextcell-files-patent-application-for-treatment-of-covid-19-with-protrans https://www.nextcellpharma.com/press-releases/nextcell-has-formally-kicked-off-its-eurostars-funded-project-bioscale https://www.nextcellpharma.com/press-releases/nextcell-has-treated-the-first-patient-in-the-protrans-repeat-trial https://www.nextcellpharma.com/press-releases/nextcell-highlighted-in-fujifilm-s-strategic-vision-according-to-gen https://www.nextcellpharma.com/press-releases/nextcell-in-discussions-about-patients-with-covid-19 https://www.nextcellpharma.com/press-releases/nextcell-in-swedish-life-science-delegation-to-hong-kong https://www.nextcellpharma.com/press-releases/nextcell-increases-market-potential-and-reduces-the-risk-of-protrans-clinical-trial-program-in-type-1-diabetes https://www.nextcellpharma.com/press-releases/nextcell-initiates-collaboration-with-opticell---strengthening-its-cell-handling-operations https://www.nextcellpharma.com/press-releases/nextcell-invests-in-car-t-technology https://www.nextcellpharma.com/press-releases/nextcell-invests-in-the-danish-cellaviva-operations-with-a-new-copenhagen-office https://www.nextcellpharma.com/press-releases/nextcell-invited-presenter-at-international-society-for-cell-and-gene-therapy-meeting-in-paris https://www.nextcellpharma.com/press-releases/nextcell-invited-speaker-at-european-wound-management-association-meeting-in-milan https://www.nextcellpharma.com/press-releases/nextcell-invited-speaker-at-the-advanced-therapy-congress-in-london https://www.nextcellpharma.com/press-releases/nextcell-invited-speaker-at-the-prestigious-advanced-therapy-week-in-usa https://www.nextcellpharma.com/press-releases/nextcell-invited-to-speak-at-advance-therapies-congress-in-london https://www.nextcellpharma.com/press-releases/nextcell-is-attending-a-conference-for-worldleading-celltherapies https://www.nextcellpharma.com/press-releases/nextcell-listed-on-the-life-science-hotlist https://www.nextcellpharma.com/press-releases/nextcell-now-has-two-parallel-running-clinical-trials-protrans-1-and-protrans-repeat-which-was-initiated-today https://www.nextcellpharma.com/press-releases/nextcell-participating-in-jetro-s-japan-entry-acceleration-program https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-announces-cfo-transition https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-comments-on-the-trading-halt-of-25-april-2019 https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-participates-in-bio-europe-2024-and-welcomes-a-visit-from-minister-ebba-busch https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-publishes-its-interim-report-for-september-2019-february-2020 https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-publishes-its-interim-report-for-september-2019-may-2020 https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-publishes-prospectus-relating-to-the-rights-issue-and-announces-the-intention-of-change-of-listing-to-nasdaq-first-north-in-july https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-receives-approval-from-ethics-committee-for-clinical-trial https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-s-rights-issue-heavily-oversubscribed https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-submits-clinical-trial-application-for-its-drug-candidate-protrans-tm https://www.nextcellpharma.com/press-releases/nextcell-pharma-ab-to-present-at-several-events-in-next-2-weeks https://www.nextcellpharma.com/press-releases/nextcell-pharma-announces-outcome-of-exercise-of-to2-and-resolves-on-directed-share-issues-to-guarantors https://www.nextcellpharma.com/press-releases/nextcell-pharma-appoints-eric-gustafsson-as-new-cfo https://www.nextcellpharma.com/press-releases/nextcell-pharma-changes-certified-adviser-to-redeye-ab https://www.nextcellpharma.com/press-releases/nextcell-pharma-changes-ticker-to-nxtcl https://www.nextcellpharma.com/press-releases/nextcell-pharma-company-presentations https://www.nextcellpharma.com/press-releases/nextcell-pharma-files-another-patent-application https://www.nextcellpharma.com/press-releases/nextcell-pharma-files-patent-application https://www.nextcellpharma.com/press-releases/nextcell-pharma-has-compiled-a-q-a-section https://www.nextcellpharma.com/press-releases/nextcell-pharma-initiates-stem-cell-trial-for-type-1-diabetes-with-protrans https://www.nextcellpharma.com/press-releases/nextcell-pharma-introduces-stem-cell-service-for-adults https://www.nextcellpharma.com/press-releases/nextcell-pharma-invited-speaker-at-the-world-advanced-therapies-regenerative-medicine-congress https://www.nextcellpharma.com/press-releases/nextcell-pharma-invited-to-present-in-tokyo https://www.nextcellpharma.com/press-releases/nextcell-pharma-presents-at-redeye-theme-regenerative-medicine-cell-therapy https://www.nextcellpharma.com/press-releases/nextcell-pharma-presents-at-redeye-theme-regenerative-medicine-cell-therapy-8aaf9 https://www.nextcellpharma.com/press-releases/nextcell-pharma-presents-at-the-advanced-therapies-europe-conference https://www.nextcellpharma.com/press-releases/nextcell-pharma-presents-historical-quarterly-figures https://www.nextcellpharma.com/press-releases/nextcell-pharma-publish-interim-report-1-2024-2025 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-annual-report-2024-2024 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-interim-report-1-2020-2021 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-interim-report-1-2021-2022 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-interim-report-2-2020-2021 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-interim-report-2-2021-2022 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-interim-report-3-2020-2021 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-interim-report-3-2021-2022 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-its-interim-report-2-2024-2025 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-its-interim-report-3-2024-2025 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-its-interim-report-4-2024-2025 https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-prospectus-relating-to-the-rights-issue https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-prospectus-supplement https://www.nextcellpharma.com/press-releases/nextcell-pharma-publishes-quarterly-report-three-2017-2018 https://www.nextcellpharma.com/press-releases/nextcell-pharma-receives-additional-declarations-of-intent-regarding-exercise-of-to2 https://www.nextcellpharma.com/press-releases/nextcell-pharma-receives-declarations-of-intent-subscription-undertakings-and-top-guarantees-regarding-exercise-of-to2 https://www.nextcellpharma.com/press-releases/nextcell-pharma-receives-wholesale-distribution-authorisation https://www.nextcellpharma.com/press-releases/nextcell-pharma-s-rights-issue-was-oversubscribed https://www.nextcellpharma.com/press-releases/nextcell-pharma-s-updated-growth-strategy https://www.nextcellpharma.com/press-releases/nextcell-pharma-updates-on-its-current-situation-in-its-first-quarterly-report https://www.nextcellpharma.com/press-releases/nextcell-pharma-updates-on-its-situation-in-its-fourth-quarter-report https://www.nextcellpharma.com/press-releases/nextcell-pharmas-clinical-trial-on-the-tv3-diabetes-gala https://www.nextcellpharma.com/press-releases/nextcell-pharmas-first-delivery-of-protrans-tm https://www.nextcellpharma.com/press-releases/nextcell-pharmas-stem-cell-study-in-type-1-diabetes-gets-green-light-from-the-medical-products-agency https://www.nextcellpharma.com/press-releases/nextcell-presentation-of-interim-analysis-data-today-at-15-00 https://www.nextcellpharma.com/press-releases/nextcell-presents-at-investerarjakten https://www.nextcellpharma.com/press-releases/nextcell-presents-detailed-analysis-of-the-administrative-report-from-protrans-young https://www.nextcellpharma.com/press-releases/nextcell-presents-quarterly-report https://www.nextcellpharma.com/press-releases/nextcell-presents-their-latest-phase-ii-clinical-data-at-isct-2021 https://www.nextcellpharma.com/press-releases/nextcell-procures-top-guarantee-in-ongoing-rights-issue https://www.nextcellpharma.com/press-releases/nextcell-provides-strategic-update-on-focused-market-progression-highlighting-hong-kong-as-gateway-to-the-chinese-market https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-interim-report-1-2022-2023 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-interim-report-1-2023-2024 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-interim-report-2-2022-2023 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-interim-report-2-2023-2024 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-interim-report-3-2022-2023 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-interim-report-3-2023-2024 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-year-end-report https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-year-end-report-2020-2021 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-year-end-report-2021-2022 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-year-end-report-2022-2023 https://www.nextcellpharma.com/press-releases/nextcell-publishes-its-year-end-report-2023-2024 https://www.nextcellpharma.com/press-releases/nextcell-publishes-opinion-piece-with-isct https://www.nextcellpharma.com/press-releases/nextcell-publishes-prospectus-in-connection-with-the-rights-issue-of-units-of-approximately-sek-40-1-million https://www.nextcellpharma.com/press-releases/nextcell-publishes-supplement-to-the-prospectus-regarding-the-rights-issue https://www.nextcellpharma.com/press-releases/nextcell-publishes-year-end-report-2024-2025 https://www.nextcellpharma.com/press-releases/nextcell-receives-us-patent-for-msc-prediction-algorithm https://www.nextcellpharma.com/press-releases/nextcell-s-ceo-invited-speaker-at-national-conference-on-clinical-studies https://www.nextcellpharma.com/press-releases/nextcell-s-cso-appointed-to-the-board-of-atmp-sweden https://www.nextcellpharma.com/press-releases/nextcell-s-cso-elected-vice-president-elect-for-isct-europe https://www.nextcellpharma.com/press-releases/nextcell-s-daughter-company-cellaviva-granted-permission-to-handle-amniotic-tissue https://www.nextcellpharma.com/press-releases/nextcell-s-phase-ii-study-is-completed-a-phase-iii-is-being-prepared https://www.nextcellpharma.com/press-releases/nextcell-s-publication-of-the-phase-i-ii-clinical-trial-in-type-i-diabetes-accepted https://www.nextcellpharma.com/press-releases/nextcell-s-rights-issue-oversubscribed https://www.nextcellpharma.com/press-releases/nextcell-signs-an-agreement-for-a-new-tissue-product https://www.nextcellpharma.com/press-releases/nextcell-strengthens-the-organization-for-continued-growth https://www.nextcellpharma.com/press-releases/nextcell-supports-protrans-study-for-children-and-adolescents https://www.nextcellpharma.com/press-releases/nextcell-to-begin-treatment-with-medium-dose-in-covid-19 https://www.nextcellpharma.com/press-releases/nextcell-to-present-its-progress-at-swiss-nordic-bio-2020 https://www.nextcellpharma.com/press-releases/nextcell-to-present-status-of-ongoing-clinical-trial-at-the-nordic-life-science-days https://www.nextcellpharma.com/press-releases/nextcell-updates-on-nls-days https://www.nextcellpharma.com/press-releases/nextcell-welcomes-consensus-sverige-selectas-as-a-shareholder https://www.nextcellpharma.com/press-releases/nextcells-biobank-cellaviva-has-received-permission-from-ivo-to-handle-stem-cells-from-adipose-tissue https://www.nextcellpharma.com/press-releases/nextcells-cso-elected-to-isct-european-regional-secretary https://www.nextcellpharma.com/press-releases/nextcells-cso-nominated-for-isct-european-regional-secretary https://www.nextcellpharma.com/press-releases/nextcells-largest-shareholder-diamyd-medical-exercise-all-of-its-warrants https://www.nextcellpharma.com/press-releases/nextcells-partner-pbkm-exercises-its-to-1-warrants https://www.nextcellpharma.com/press-releases/nordic-tech-house-to-invest-in-stem-cell-company-nextcell-pharma https://www.nextcellpharma.com/press-releases/notice-of-extraordinary-general-meeting-in-nextcell-pharma-ab-publ https://www.nextcellpharma.com/press-releases/notice-of-extraordinary-general-meeting-in-nextcell-pharma-ab-publ-b8733 https://www.nextcellpharma.com/press-releases/notice-to-attend-the-annual-general-meeting https://www.nextcellpharma.com/press-releases/nxtcl-is-allocated-approximately-sek-12-9-million-through-redemption-of-warrants https://www.nextcellpharma.com/press-releases/nxtcls-cellaviva-brand-is-expanding-into-denmark https://www.nextcellpharma.com/press-releases/participates-in-innovation-projects-for-cell-based-products https://www.nextcellpharma.com/press-releases/patients-in-the-first-part-of-pediatric-diabetes-trial-with-nextcells-protrans-treated https://www.nextcellpharma.com/press-releases/patients-treated-with-protrans-in-phase-ii-of-the-clinical-trial https://www.nextcellpharma.com/press-releases/pediatric-diabetes-study-with-protrans-in-progress https://www.nextcellpharma.com/press-releases/pediatric-diabetes-study-with-stem-cells-approved https://www.nextcellpharma.com/press-releases/positive-feedback-on-the-paediatric-plan-of-the-ema https://www.nextcellpharma.com/press-releases/presentation-of-the-pediatric-diabetes-study-tomorrow-wednesday https://www.nextcellpharma.com/press-releases/presentation-of-the-positive-results-from-protrans-2 https://www.nextcellpharma.com/press-releases/promising-results-from-clinical-trial-with-protrans-stem-cells https://www.nextcellpharma.com/press-releases/protrans-and-nextcell-gain-international-attention https://www.nextcellpharma.com/press-releases/protrans-cell-therapy-maintains-insulin-production-effect-3-5-years-after-treatment https://www.nextcellpharma.com/press-releases/protrans-cell-therapy-provides-long-term-effect-in-type-1-diabetes-with-a-single-treatment https://www.nextcellpharma.com/press-releases/protrans-cell-therapy-to-be-granted-patent-protection-beyond-europe https://www.nextcellpharma.com/press-releases/protrans-demonstrates-effect-at-2-years-after-repeated-treatments https://www.nextcellpharma.com/press-releases/protrans-highlighted-as-a-promising-treatment-for-type-1-diabetes-in-dagens-medicin https://www.nextcellpharma.com/press-releases/protrans-observation-study-for-long-term-efficacy-in-diabetes https://www.nextcellpharma.com/press-releases/protrans-phase-ii-covid-19-trial-accepted-for-publication-in-cytotherapy https://www.nextcellpharma.com/press-releases/protrans-repeat-an-approved-clinical-trial-for-repeated-treatment-of-patients-with-diabetes https://www.nextcellpharma.com/press-releases/protrans-shows-significant-effect-in-diabetes https://www.nextcellpharma.com/press-releases/protrans-stem-cells-approved-for-clinical-trials-in-covid-19-patients https://www.nextcellpharma.com/press-releases/protrans-study-in-covid-19-expanded-to-include-treatment-of-severe-pneumonia-induced-by-influenza-a-rsv-and-hmp-virus https://www.nextcellpharma.com/press-releases/protrans-trial-is-approved-for-high-dose-treatment-in-the-phase-ii-part https://www.nextcellpharma.com/press-releases/publication-of-annual-report-2017-2018 https://www.nextcellpharma.com/press-releases/publication-of-scientific-article-regarding-the-clinical-trial-with-protrans https://www.nextcellpharma.com/press-releases/publication-of-year-end-report https://www.nextcellpharma.com/press-releases/qvance-ab-publishes-article-on-particulates-in-cell-and-gene-therapy-products-in-collaboration-with-isct https://www.nextcellpharma.com/press-releases/qvance-announces-partnership https://www.nextcellpharma.com/press-releases/qvance-s-partnerships-driving-innovation-in-advanced-therapies https://www.nextcellpharma.com/press-releases/recognition-for-nextcell-s-cso-from-the-international-society-of-cell-and-gene-therapy https://www.nextcellpharma.com/press-releases/recruitment-start-for-the-protrans-study-for-treatment-of-covid-19 https://www.nextcellpharma.com/press-releases/rectification-six-out-of-nine-patients-in-the-first-part-of-the-phase-i-ii-trial-protrans-1-have-completed-treatment https://www.nextcellpharma.com/press-releases/redeemed-warrants-are-now-registered-with-the-swedish-companies-registration-office https://www.nextcellpharma.com/press-releases/reminder-to-exercise-your-series-to-1-warrants https://www.nextcellpharma.com/press-releases/repeated-treatment-with-protrans-is-immunologically-safe https://www.nextcellpharma.com/press-releases/republishing-of-nextcell-announces-strategic-collaboration-with-fujifilm-biosciences https://www.nextcellpharma.com/press-releases/results-from-the-older-age-cohort-in-the-protrans-young-paediatric-study-expected-in-aprilv https://www.nextcellpharma.com/press-releases/saving-of-stem-cell-from-births-increases-significantly-for-nextcell-s-biobank-cellaviva https://www.nextcellpharma.com/press-releases/selected-to-participate-in-the-eit-health-start-smart-global-ssg-programme https://www.nextcellpharma.com/press-releases/seven-year-follow-up-data-from-protrans-repeat-demonstrate-sustained-disease-modifying-effects-of-protrans-in-type-1-diabetes https://www.nextcellpharma.com/press-releases/single-treatment-with-protrans-demonstrates-long-term-therapeutic-effect-over-5-years https://www.nextcellpharma.com/press-releases/six-out-of-nine-patients-in-the-phase-ii-part-of-the-protrans-1-study-have-completed-treatment https://www.nextcellpharma.com/press-releases/six-patients-now-treated-with-nextcells-protrans-stem-cells https://www.nextcellpharma.com/press-releases/six-year-data-demonstrate-a-durable-disease-modifying-effect-of-protrans-in-type-1-diabetes https://www.nextcellpharma.com/press-releases/stem-cell-company-nextcell-pharma-receives-approval-from-ethics-committee https://www.nextcellpharma.com/press-releases/study-design-and-plan-for-the-recently-approved-covid-19-study-with-protrans https://www.nextcellpharma.com/press-releases/study-published-in-nature-medicine-shows-promising-results-in-alzheimer-s-disease---supports-the-development-of-protrans-at-nextcell https://www.nextcellpharma.com/press-releases/study-start-for-protrans-in-covid-19 https://www.nextcellpharma.com/press-releases/subgroup-analysis-nextcell-presents-preliminary-one-year-results-from-the-older-age-group-in-protrans-young https://www.nextcellpharma.com/press-releases/summary-of-exercised-warrants-by-board-members-and-senior-executives-in-nxtcl https://www.nextcellpharma.com/press-releases/the-board-of-directors-and-management-sign-in-addition-to-subscription-commitments https://www.nextcellpharma.com/press-releases/the-board-of-directors-of-nextcell-pharma-ab-resolves-on-a-fully-guaranteed-sek-25-1-million-rights-issue https://www.nextcellpharma.com/press-releases/the-board-of-directors-of-nextcell-pharma-intends-on-resolving-on-a-fully-guaranteed-preferential-rights-issue-of-approximately-sek-150-million https://www.nextcellpharma.com/press-releases/the-board-of-directors-of-nextcell-resolves-on-a-rights-issue-of-units-of-approximately-sek-40-1-million-subject-to-approval-by-an-extraordinary-general-meeting https://www.nextcellpharma.com/press-releases/the-canadian-protrans-in-covid-19-single-center-trial-is-expanded-to-a-multicenter-trial https://www.nextcellpharma.com/press-releases/the-data-and-safety-monitoring-board-approves-the-usage-of-high-dose-protrans-in-the-ongoing-clinical-trial https://www.nextcellpharma.com/press-releases/the-data-and-safety-monitoring-board-approves-the-usage-of-medium-dose-protrans-in-the-ongoing-clinical-trial https://www.nextcellpharma.com/press-releases/the-european-patent-office-intends-to-grant-a-patent-for-selection-algorithm https://www.nextcellpharma.com/press-releases/the-exercise-period-for-nextcell-pharma-s-warrants-of-series-to2-begins-today https://www.nextcellpharma.com/press-releases/the-first-children-have-been-treated-in-the-younger-age-group-of-the-protrans-young-study https://www.nextcellpharma.com/press-releases/the-medical-products-agency-grants-nextcell-permission-to-initiate-the-protrans-repeat-trial https://www.nextcellpharma.com/press-releases/the-nextcell-pharma-ab-board-of-directors-proposes-an-rights-issue-of-msek-24-9-and-calls-for-an-extraordinary-general-meeting https://www.nextcellpharma.com/press-releases/the-paediatric-diabetes-study-gets-the-green-light-to-treat-the-age-group-7---11-years https://www.nextcellpharma.com/press-releases/the-safety-committee-recommends-proceeding-with-part-2-of-the-stem-cell-trial-in-type-1-diabetes https://www.nextcellpharma.com/press-releases/the-stem-cell-company-nextcell-invests-in-own-production-facility https://www.nextcellpharma.com/press-releases/the-stem-cell-company-nextcell-pharma-is-preparing-for-a-pivotal-phase-iii-trial https://www.nextcellpharma.com/press-releases/the-stem-cell-company-nextcell-pharma-participates-as-a-reference-laboratory-in-nibsc-study https://www.nextcellpharma.com/press-releases/the-subscription-period-in-nextcell-s-rights-issue-commences-today https://www.nextcellpharma.com/press-releases/the-subscription-period-of-the-series-to-1-warrants-starts-today https://www.nextcellpharma.com/press-releases/the-swedish-medical-products-agency-approves-subgroup-analysis-in-nextcell-s-protrans-young-study https://www.nextcellpharma.com/press-releases/three-patients-now-treated-with-nextcells-protrans-stem-cells https://www.nextcellpharma.com/press-releases/today-nextcell-pharma-publishes-its-annual-report-2016-2017 https://www.nextcellpharma.com/press-releases/today-nextcell-publishes-its-half-year-report https://www.nextcellpharma.com/press-releases/treatment-start-of-severe-pneumonia-with-high-dose-of-protrans https://www.nextcellpharma.com/press-releases/upcoming-events-and-conferences-for-nxtcl https://www.nextcellpharma.com/press-releases/update-on-nextcell-pharmas-clinical-trial-application https://www.nextcellpharma.com/press-releases/update-on-the-ongoing-clinical-trials https://www.nextcellpharma.com/press-releases/update-regarding-possible-merger-between-nextcell-pharma-ab-and-idogen-ab https://www.nextcellpharma.com/press-releases/update-regarding-targeted-new-issue-to-nordic-tech-house https://www.nextcellpharma.com/press-releases/updates-regarding-nextcell-s-clinical-trials-with-protrans https://www.nextcellpharma.com/press-releases/year-end-report-2018-09-01-2019-08-31